Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer
Top Cited Papers
- 1 August 2002
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (15) , 3219-3224
- https://doi.org/10.1200/jco.2002.11.080
Abstract
PURPOSE: The development of bone metastases depends on tumor-induced osteoclastic resorption of bone, which may be inhibited by the antiosteolytic bisphosphonate clodronate. Given to patients with ...Keywords
This publication has 13 references indexed in Scilit:
- Bisphosphonates in the prevention of bone metastases: Current evidenceSeminars in Oncology, 2001
- Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 1999
- Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate TreatmentNew England Journal of Medicine, 1998
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Clodronate decreases the frequency of skeletal metastases in women with breast cancerBone, 1996
- Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.Journal of Clinical Oncology, 1993
- BisphosphonatesDrugs, 1991
- LONG-TERM CONTROLLED TRIAL WITH DIPHOSPHONATE IN PATIENTS WITH OSTEOLYTIC BONE METASTASESThe Lancet, 1983
- Mechanisms of bone destruction in the development of skeletal metastasesNature, 1976
- The Inhibition by Aspirin and Indomethacin of Osteolytic Tumour Deposits and Hypercalcaemia in Rats with Walker Tumour, and its Possible Application to Human Breast CancerBritish Journal of Cancer, 1973